46results about How to "Low inhibition rate" patented technology

A magnetic field device and method for inhibiting angiogenesis and retarding growth rates of cancerous tumors present in mammals. The apparatus includes a frame, and a wire consisting of electrically conducting material. The wire is wrapped around the frame to form a coil. A source of AC current is connected to a transformer to vary the AC voltage. The AC current is passed through a bridge rectifier and then to the coil of wire enabling a DC rectified wave magnetic field to be produced therefrom. The method employs the use of an apparatus which is capable of producing a magnetic field of a particular nature which has been proven in animal studies to affect angiogenesis and retard the growth rate of cancerous tumors.

The invention discloses an interventional medical appliance and a manufacturing method thereof. The interventional medical appliance comprises a bracket body, wherein the surface of the bracket body is provided with a medicament releasing structure; and a medicament in the medicament releasing structure is a medicament for restraining proliferation of adventitial fibroblasts. When the interventional medical appliance is transplanted into a human body, the medicament for restraining the proliferation of adventitial fibroblasts can be slowly released into vessel wall cells contacted with the bracket body, so that the proliferation of the adventitial fibroblasts can be restrained, the compensatory expansion of vessels is promoted, and the incidence rate of restenosis in the bracket is lowered.

Enzyme immunoassay method for detecting Kebaiwei includes (1) synthesizing half antigen and artificial antigen; (2) preparing polyclonal antibody, monoclonal antibody, or gene engineering antibody of possessing specificity to Kebaiwei; (3) preparing enzyme labeled antigen; (4) using second antibody to coat enzyme labeled plate and close the plate to save Kebaiwei; reaction is carried out between anti Kebaiwei antibody and second antibody and fixed on the enzyme labeled plate; (5) washing out free object, adding sample to be tested, and enzyme labeled antigen or Kebaiwei labeled sample, and enzyme labeled antigen; (6) washing out free object, adding substrate of enzyme and developer. Intensity of enzyme promoting color reaction is proportional to quantity of enzyme labeled antigen bound on antibody, and is inversely proportional to content of Kebaiwei in sample. Features are: long term storage, increasing sensitivity, accuracy, simple and quick test operation.

The invention discloses salts prepared from 2-(1-acyloxy-n-amyl)benzoic acid and basic amino acid or aminoguanidine, a preparation method thereof, a medicinal preparation containing the salts, and application of the salts to preparing of medicines used for preventing or treating ischemic cardiovascular and cerebral vascular diseases, resisting thrombus and relieving cardio-cerebral circulatory disturbance. A compound not only has good water solubility, aqueous solution stability and pharmacokinetics performance, but also has strong activity for resisting platelet aggregation, resisting thrombus, resisting cerebral ischemia and protecting nerves, the effect is superior to that of (S)-butylphthalide and (R / S)-2-(1-hydroxy-n-amyl)potassium benzoate salt (PHPB), acute toxicity of the compoundto mouse intravenous injection dosing is remarkably lower than that of butylphthalide and PHPB, the inhibition ratio of the compound to an hERG potassium channel of a CHO-hERG cell is lower than thatof the (S)-butylphthalide, and a result of a bacterial reverse mutation test (Ames test) is negative.

The invention discloses a nanometer antibody resistant to pseudomonas aeruginosa ectotoxin A and application of the nanometer antibody. The nanometer antibody has 3 unique complementary determining regions CDR1, CDR2 and CDR3, and the application relates to application of the nanometer antibody in preparation of a drug resistant to the pseudomonas aeruginosa ectotoxin A. The nanometer antibody resistant to the pseudomonas aeruginosa ectotoxin A has specific identification and combination capacity to the pseudomonas aeruginosa ectotoxin A, and can effectively neutralize the toxic effect of thepseudomonas aeruginosa ectotoxin A, thereby playing a role in protecting normal cells.

The invention discloses a strain of bacillus amyloliquefaciens with an inhibiting effect on fusarium oxysporum and application of the bacillus amyloliquefaciens. The fusarium oxysporum (FON) is pathogenic bacteria of watermelon fusarium wilt, and biological control is a crucial method for controlling the watermelon fusarium wilt. A bacterial strain for inhibiting the FON is screened from wheat rhizosphere, and the bacterial strain is Bacillus amyloliquefaciens LZN01 through authentication. Experimental results show that the antibacterial rate of the Bacillus amyloliquefaciens LZN01 to the FONis 57.07%, and the spore germination inhibition ratio of the Bacillus amyloliquefaciens LZN01 to the FON is 86.21%. Under the conditions that the temperature is 20-60 DEG C and the pH value is 4-9, the antibacterial effect of a fermented supernatant fluid of the Bacillus amyloliquefaciens LZN01 is stable, and antibacterial substances of the supernatant fluid contain Myriocin, Sphingofungin E, Sphingofungin F, Sphingofungin C and Gabapentin. Therefore, the Bacillus amyloliquefaciens LZN01 has a better inhibiting ability to the FON, the antibacterial effect is stable, and the development and application value is larger in biological control of the watermelon fusarium wilt.

The invention discloses a hydrogen peroxide-responsive nitrogen mustard anti-tumor pro-drug and a preparation method thereof, and belongs to the field of pharmaceutical chemistry. The compound contains an alpha-ketoamide structure and a nitrogen mustard structure, can rapidly respond to H2O2, can be used as the nitrogen mustard anti-tumor pro-drug, has good response effect to H2O2, has high cell selectivity and small toxic and side effects, provides an effective, safe and highly selective anti-tumor drug, enriches the types of nitrogen mustard anti-tumor drugs, and has a good market prospect.

Disclosed is a light source combination method. The light source combination method comprises the steps of (1) providing a plurality of light-emitting components, and driving the light-emitting components to give out multiple colored lights; (2) determining whether a Planck curve in a CIE coordinate graph is surrounded by multiple CIE coordinate positions corresponding to the multiple colored lights or not; if so, executing a step (3), and if not, executing the step (1) repeatedly; (3) mixing the multiple colored lights into one mixed light, wherein the mixed light has a specific CIE coordinate; (4) determining whether the specific CIE coordinate is positioned above the Planck curve in the CIE coordinate graph or not; if so, executing a step (6), and if not, executing a step (5); (5) driving the light-emitting components to adjust light intensity of one or more colored lights, and executing the step (3) repeatedly; and (6) performing further integration on the light-emitting components to form a light emitting unit or a light emitting module, wherein the light emitting unit or the light emitting module can give out a high-quality light source. By virtue of the method and the process, the light emitting unit which can give out the high-quality light source can be combined and manufactured by an engineer favorably.

The present application discloses an interventional medical device and a preparation method thereof. The interventional medical device comprises: a stent body, the surface of the stent body is provided with a drug release structure, and the drug in the drug release structure inhibits adventitial fibroblasts Proliferative drugs and drugs that inhibit intima and / or smooth muscle cell proliferation. When the interventional medical device is implanted into the human body, the drug that inhibits the proliferation of adventitial fibroblasts carried on it can be slowly released into the blood vessel wall cells that are in contact with the stent body, thereby inhibiting adventitial fibroblasts. The proliferation of cells promotes the compensatory expansion of blood vessels. At the same time, the drugs carried on it that inhibit the proliferation of intima and / or smooth muscle cells can also inhibit the proliferation of vascular intimal to a certain extent. The two drugs work together to greatly reduce the The incidence of internal restenosis.

The invention discloses substituted-pyrrolidinyl-contained thiomorpholine compounds, a preparation method thereof and applications thereof. In concrete, the invention relates to compounds having a general formula (I), stereoisomers of the compounds and pharmaceutical acceptable salts of the compounds, wherein R is shown in the specification. The invention also relates to pharmaceutical compositions comprising the compounds, and the applications of the compounds in preparing medicines used for treating and / or preventing a disease or a symptom which are related to over-high activity of DPP-IV or over-expression of the DPP-IV, and also relates to a method of using the compounds for treating related diseases. The compounds have activity for effectively inhibiting the DPP-IV.

The invention provides an application of echinacoside to preparation of a product for treating pruritus by inhibiting a transient receptor potential vanillin receptor 3 channel. The inhibiting effectof the echinacoside on the transient receptor potential vanillin receptor 3 channel is verified by a calcium fluorescence method and a manual patch clamp technique, and the median inhibitory concentration IC50 of the echinacoside for the transient receptor potential vanillin receptor 3 channel is 14.7+ / -0.6 micrometers. The echinacoside is a specific inhibitor of the transient receptor potential vanillin receptor 3 channel. The anti-pruritus activity of the echinacoside is evaluated by a mouse skin pruritus model, and the echinacoside has an anti-pruritus effect on mouse acute pruritus causedby histamine. The echinacoside serving as the inhibitor of the transient receptor potential vanillin receptor 3 channel can be used for preparing the product for treating pruritus by inhibiting the transient receptor potential vanillin receptor 3 channel.

The present invention relates to a strip-shaped electrode used for a cylindrical jelly roll in which a strip-shaped electrode assembly is wound in a cylindrical shape such that a hollow space is formed at a core part thereof, and a lithium secondary battery comprising the same, the strip-shaped electrode comprising: a strip-shaped electrode current collector; a first electrode active material layer formed on at least one surface of the strip-shaped electrode current collector; and a second electrode active material layer formed on the first electrode active material layer, wherein the second electrode active material layer is formed to be shorter than the first electrode active material layer such that the first electrode active material layer has one lengthwise side surface, a part of which is exposed to the outside.

The invention discloses pulse stimulation equipment capable of effectively avoiding pacing in an atrial vulnerable period. The pulse stimulation equipment comprises an atrial sensing module, a pacing control module, an atrial pacing module, a clock / timing module and a storage module, the atrium sensing module senses and sends an atrium activity signal to the pace-making control module; when the pace-making control module recognizes an atrial activity signal as an atrial perception event in a non-stress period, the clock / timing module is controlled to time a T1 period and a T2 period which are stored in the storage module and adjacent in time sequence according to the T1 period and the T2 period which are stored in the storage module and adjacent in time sequence; the pacing control module inhibits the atrial pacing module from issuing an atrial pacing event when it is determined that the expected atrial pacing event occurs at the T2 period. The problem of atrial fibrillation danger caused by pacing in the atrial vulnerable period is solved.

The invention discloses a sputum pretreatment method for quickly carrying out nucleic acid detection. The sputum pretreatment method comprises the following steps of a first step, adding a NaOH solution with a concentration of 4 to 30 percent into a collected sputum specimen, wherein the amount of the NaOH solution is 4 times that of the collected sputum specimen, carrying out vortex oscillation to liquefy the collected sputum specimen, and standing for 5min to 10min at a room temperature; a second step, adding a citric acid solution with a concentration of 20 to 80 percent into specimen liquid treated in the first step, and uniformly oscillating and mixing; a third step, adding thiourea with a concentration of 5 to 14 percent into specimen liquid treated in the second step, uniformly oscillating and mixing, then standing at the room temperature, and removing a deposit. The sputum pretreatment method has the advantages that the method is simple and quick, as the entire pretreatment process does not need centrifugation, the operation is convenient, and the consumed time is shorter (less than 15 minutes); the specimen liquid pretreated by the method provided by the invention is higher in sensitivity; 30 bacteria per milliliter can be lowest detected; the specificity is good, and according to a clinical specimen verification result, the negative coincidence rate can reach 100 percent.

The invention discloses a method for high-flux screening of drugs used for pseudorabies viruses. The method comprises the following steps of 1, inoculating a white optical-bottom 96-well cell plate with IBRS-2 cells, and carrying out culture in an incubator containing 5% of CO2 and having a temperature of 37 DEG C, 2, removing a growth solution, adding a maintenance media into the culture product, adding compounds needing to be screened into the culture product, orderly carrying out coubling dilution, carrying out uniform mixing, adding a pseudorabies virus Hubei A strain into each one of the wells of the white optical-bottom 96-well cell plate, and arranging a control group without the pseudorabies viruses and the compounds, and a control group with the pseudorabies viruses and without the compounds on the same white optical-bottom 96-well cell plate, wherein the compounds are dissolved in dimethylsulfoxide, 3, carrying out continue culture in the incubator containing 5% of CO2 and having a temperature of 37 DEG C, adding a Celltiterglo reagent into the culture, carrying out detection in a high-flux chemical luminescent detector, and calculating inhibition ratios of the compounds, and 4, utilizing the compound having a high inhibition rate as a potential drug for resisting pseudorabies viruses. The method is simple and fast, has a low cost, is convenient for high flux operation, can be used for screening aiming at the whole proliferation process of pseudorabies viruses in cells, and has a high success rate.

The invention discloses application of an aspartic protease gene in improvement of beauveria bassiana variety. The yield and toxicity of conidia of the beauveria bassiana are improved by knocking out the aspartic protease gene BbASP, or the high-temperature tolerance of the beauveria bassiana is improved by over-expressing the aspartic protease gene BbASP, and the nucleotide sequence of the aspartic protease gene BbASP is as shown in SEQ ID NO. 20; if the BbASP knockout strain is cultured for 10 d at 26 DEG C, the conidium yield is 72.57% higher than that of a wild type, if the BbASP knockout strain is cultured for 20 d at 26 DEG C, the conidium yield is 59.43% higher than that of a wild type, the survival rate of a host is reduced, the half lethal time is shortened, the time that entomogenous thalli penetrate out of the dead host is shortened, and the growth rate of the BbASP over-expression strain is increased under the high-temperature stress of 32 DEG C; and after the conidia are stressed at the high temperature of 43 DEG C for 2 h and 4 h, the germination rates are respectively increased by 7% and 11.34%.

The invention discloses preparation and application of a human serum albumin-NAMI-A ruthenium inorganic medicine compound. NAMI-A and the human serum albumin are incubated, the mixture is concentrated, the concentrated mixture is repeatedly washed by secondary deionized water till the DMSO content is smaller than 0.01 percent, then concentration is performed to obtain the human serum albumin-NAMI-A ruthenium inorganic medicine compound, and the compound is prepared into an injection, tablets, pills, capsules, a suspending agent or an emulsion to treat breast cancer, stomach cancer, lung cancer, colon cancer or liver cancer. The compound has high vascular permeability and retention rate, the medicine selectivity gathers in tumor cells while not influencing normal cells, the targeting of the ruthenium inorganic medicine is remarkably improved and the toxicity is greatly lowered.

The invention discloses a red-section Smilax ocreafa A. DC effective part and a use thereof. A general flavone part is an effective part of red-section Smilax ocreafa A. DC. A ratio of the flavones components to general flavone part solids of the general flavone part is more than 90%. Through repeated tests, screening, comparison and summarizing, the preparation method (extraction method) of an effective part general flavone part of red-section Smilax ocreafa A. DC is determined. A test result shows that based on a peak area of a main chemical component astilbin of red-section Smilax ocreafa A. DC, astilbin content is 59.8%, based on the sum of peak areas of all flavones, flavones content is 94.2% and the general flavone part has high purity and good effects. The test result shows that the preparation method has good repeatability and good stability.

The invention relates to a pyrrolopyrimidine ketone compound and a preparation method and application thereof, and belongs to the technical field of medicine. The pyrrolopyrimidine ketone compound having a structural feature of formula I, or a pharmaceutically acceptable salt thereof has a very good inhibition effect on DPP-IV, and almost no effect on activity of DPP-VIII and DPP-IX, can effectively control the blood glucose concentration of diabetic rats, and is safe and low in toxicity through the verification of pharmacological and toxicological tests. After being prepared into a medicine, the compound provided by the invention not only has an obvious efficacy but also has very small side effects, thus greatly improving the administration convenience and patient use compliance, therefore, the compound has obvious advantages compared with the same kind of medicine. The formula is shown in the specification.

The invention discloses rosemary foot bath powder and a preparation method thereof. The rosemary foot bath powder disclosed by the invention comprises the following components in parts by weight: 10-25 parts of rosemary, 3-10 parts of geranium, 3-8 parts of pogostemon cablin, 4-9 parts of folium cortex eucommiae, 1-3 parts of grape pip, 1-5 parts of rose, and 2-6 parts of ginger powder. The preparation method disclosed by the invention comprises the steps of removing impurities, air-drying, fermenting, sterilizing, carrying out enzymolysis, drying, compounding and crushing. The rosemary foot bath powder disclosed by the invention is rapid to take effect and has much soluble substances; and the rosemary foot bath powder can have a better health effect without being soaked for a long time and is short in use period and low in cost.

The invention discloses a pure natural alcohol-free oral cleaning care solution which is prepared from the following raw materials in percentage by weight: 10-20% of pogostemon cablin hydrolat, 10-20% of lemongrass hydrolat, 20-30% of lavender hydrolat, 10-20% of peppermint hydrolat, 5-10% of rosemary hydrolat, 3-8% of litsea cubeba hydrolat, 3-8% of melaleuca alternifolia hydrolat, 10-20% of parsley hydrolat and 0.1-0.3% of clove bud essential oil. By adopting natural extracts of aromatic plants as main components, the oral cleaning care solution is capable of strengthening the human immunity and pleasuring the mind and body while effectively refreshing the breath, killing bacteria, resisting dental caries and improving the antioxidant capacity; by virtue of improvement on the formula, the problem of use security of mouth wash on the market at present is effectively solved.

The invention discloses sterilizing and acarus-killing compound essential oil. The essential oil comprises a solvent and essential oil. The essential oil comprises 0.02-0.04% of bergamot essential oil, 0.04-0.06% of lemon essential oil, 0.01-0.03% of rosemary essential oil, and 0.01-0.02% of pepper and mint essential oil; 0.01%-0.02% of eucalyptus essential oil; The solvent comprises the followingcomponents by mass: 8090% of water; 2.0-5.0% of a PPG-26-butanol polyether-26; 2.0-5.0% of propylene glycol; 1.0-2.0% of PEG-40 hydrogenated castor oil; 2.0-5.0% of 1, 2-hexanediol; 2.0-5.0% of 1, 3-propylene glycol; and 0.01-0.05% of capryloyl hydroxamic acid. The sterilizing and acarus-killing compound essential oil can effectively remove mites, has a good killing effect, is non-toxic and harmless, and has no side effects on the environment and human bodies.

The invention relates to a rice seed treatment agent, which comprises effective components and auxiliary agents, wherein the mass of the effective components accounts for 5-85% of the total mass of the rice seed treatment agent, the effective components are isoxadifen and gibberellin, and the auxiliary agents comprise three or more than three materials selected from a surfactant, a solvent, a suspending auxiliary agent and an anti-freezing agent. According to the present invention, the rice seed treatment agent can treat rice seeds, can improve the drug resistance on fenoxaprop-P-ethyl and other herbicides at the rice seedling stage, can improve the selectivity between rice and other malicious weeds such as weedy rice and the like of herbicides, can ensure the seedling emergence rate of rice, and can reduce the influence on the germination rate of rice seeds during the single treatment with isoxadifen.

The invention relates to a daphnoretin micelle and a preparation method, content detection and application thereof. The daphnoretin nano-micelle is prepared by selecting a safe and degradable material PEG-PLA, and daphnoretin is prepared into a polymer micelle so as to achieve the purposes of increasing solubility and prolonging in-vivo action time. Meanwhile, the glycyrrhetinic acid coupled PEG-PLA is used as a carrier, and the nano preparation which is loaded with daphnoretin and has the liver cancer targeting property is prepared. Through in-vitro cell research, in-vivo targeting evaluation and preliminary pharmacodynamic research on the two drug-loaded micelles, the liver targeting drug delivery performance and the anti-tumor effect of the daphnoretin nano-micelle drug system are proved, and a theoretical basis is laid for in-vivo liver cancer targeting research of daphnoretin in the future; and a new thought is provided for the development of a new daphnoretin dosage form and a novel liver cancer targeting preparation.

The invention provides a thienopyrimidinone compound or pharmaceutically-acceptable salt thereof and a preparation method and application thereof. The thienopyrimidinone compound or the pharmaceutically-acceptable salt thereof has a novel chemical structure, it is verified through in-vitro and in-vivo experiments that a very good selective inhibiting effect on DPP-IV is achieved, the activity of DPP-VIII and DPP-IX is barely affected while the activity of DPP-IV is effectively inhibited, meanwhile, the inhibition ratio of a potassium ion channel is low, and it can be predicted that the toxicity is low after the compound is developed into medicine. Compared with medicine trelagliptin orally taken once every week on the market, the thienopyrimidinone compound has fairly high or higher bioavailable efficiency, it can be predicted that after the compound is developed, the treatment effect that the compound is orally taken once for a long time, and the convenience and compliance of a patient are greatly improved. The preparation method is simple, the raw materials are easy to obtain, and the preparation method is suitable for industrial large-scale production.

The invention discloses a privacy protection method for a sparse position trajectory, a position point candidate set is obtained by dynamically adjusting an anonymity threshold, the dynamic position anonymity threshold can reduce inhibition and reduce a trajectory point inhibition rate compared with a static position anonymity threshold, and in addition, historical data of a user is not adopted asthe basis of a false trajectory. Direct exposure of data is avoided; and finally, connecting the position points in the position point candidate set by judging the accessibility between the adjacentposition points and combining the local transition probability to obtain a candidate track set. And similarity judgment is performed between the tracks in the candidate track set and the original track, and the optimal k-1 tracks are selected from the candidate track set in combination with the overall transition probability, so that the analysis on the transition probability can be effectively resisted, and the anonymous effect is greatly improved.

The invention discloses thiomorpholine compounds containing substituted pyrrole alkyl groups, a preparation method and applications thereof. Specifically, the invention relates to compounds represented by the formula (1), stereo isomers, and pharmaceutically-acceptable salts thereof; wherein the R is detailed in the description. The invention further relates to a pharmaceutical composition containing the provided compounds, applications of the compounds in preparation of drugs for treating and / or preventing diseases or symptoms caused by too high activity of DPP-IV or over expression of DPP-IV, and methods using the compounds to treat the diseases mentioned above. The compounds can effectively inhibit the activity of DPP-IV.

The invention discloses a hydrogen peroxide-responsive nitrogen mustard anti-tumor pro-drug and a preparation method thereof, and belongs to the field of pharmaceutical chemistry. The compound contains an alpha-ketoamide structure and a nitrogen mustard structure, can rapidly respond to H2O2, can be used as the nitrogen mustard anti-tumor pro-drug, has good response effect to H2O2, has high cell selectivity and small toxic and side effects, provides an effective, safe and highly selective anti-tumor drug, enriches the types of nitrogen mustard anti-tumor drugs, and has a good market prospect.